BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer 2021;20:55. [PMID: 33761944 DOI: 10.1186/s12943-021-01346-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Yasin D, Sami N, Afzal B, Husain S, Naaz H, Ahmad N, Zaki A, Rizvi MA, Fatma T. Prospects in the use of gold nanoparticles as cancer theranostics and targeted drug delivery agents. Appl Nanosci 2022. [DOI: 10.1007/s13204-022-02701-5] [Reference Citation Analysis]
2 Jafari M, Kadkhodazadeh M, Shapourabadi MB, Goradel NH, Shokrgozar MA, Arashkia A, Abdoli S, Sharifzadeh Z. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Front Immunol 2022;13:1012806. [DOI: 10.3389/fimmu.2022.1012806] [Reference Citation Analysis]
3 Rajh T, Koritarov T, Blaiszik B, Rizvi SFZ, Konda V, Bissonnette M. Triggering cell death in cancers using self-illuminating nanocomposites. Front Chem 2022;10:962161. [DOI: 10.3389/fchem.2022.962161] [Reference Citation Analysis]
4 Ko C, Zang S, Zhou Y, Zhong Z, Yang C. Nanocarriers for effective delivery: modulation of innate immunity for the management of infections and the associated complications. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01582-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tian C, Zheng S, Liu X, Kamei KI. Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system. J Nanobiotechnology 2022;20:338. [PMID: 35858898 DOI: 10.1186/s12951-022-01552-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Eras A, Castillo D, Suárez M, Vispo NS, Albericio F, Rodriguez H. Chemical Conjugation in Drug Delivery Systems. Front Chem 2022;10:889083. [DOI: 10.3389/fchem.2022.889083] [Reference Citation Analysis]
7 Maslennikova A, Mazurov D. Application of CRISPR/Cas Genomic Editing Tools for HIV Therapy: Toward Precise Modifications and Multilevel Protection. Front Cell Infect Microbiol 2022;12:880030. [DOI: 10.3389/fcimb.2022.880030] [Reference Citation Analysis]
8 Heshmati Aghda N, Dabbaghianamiri M, Tunnell JW, Betancourt T. Design of Smart Nanomedicines for Effective Cancer Treatment. Int J Pharm 2022;:121791. [PMID: 35525473 DOI: 10.1016/j.ijpharm.2022.121791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zattoni IF, Delabio LC, de Paula Dutra J, Kita DH, Scheiffer G, Hembecker M, da Silva Pereira G, Moure VR, Valdameri G. Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114346] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
10 Volovat S, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics 2022;14:397. [DOI: 10.3390/pharmaceutics14020397] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Kang SR, Nguyen DH, Yoo SW, Min JJ. Bacteria and bacterial derivatives as delivery carriers for immunotherapy. Adv Drug Deliv Rev 2022;181:114085. [PMID: 34933064 DOI: 10.1016/j.addr.2021.114085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
12 Miao Y, Yang T, Yang S, Yang M, Mao C. Protein nanoparticles directed cancer imaging and therapy. Nano Converg 2022;9:2. [PMID: 34997888 DOI: 10.1186/s40580-021-00293-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Gagliardi M, Ashizawa AT. Making Sense of Antisense Oligonucleotide Therapeutics Targeting Bcl-2. Pharmaceutics 2022;14:97. [PMID: 35056993 DOI: 10.3390/pharmaceutics14010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Belleri M, Chiodelli P, Corli M, Capra M, Presta M. Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme β-galactosylceramidase. Biochim Biophys Acta Rev Cancer 2021;1877:188675. [PMID: 34974112 DOI: 10.1016/j.bbcan.2021.188675] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ulfo L, Cantelli A, Petrosino A, Costantini PE, Nigro M, Starinieri F, Turrini E, Zadran SK, Zuccheri G, Saporetti R, Di Giosia M, Danielli A, Calvaresi M. Orthogonal nanoarchitectonics of M13 phage for receptor targeted anticancer photodynamic therapy. Nanoscale 2021. [PMID: 34792088 DOI: 10.1039/d1nr06053h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Lai WH, Fang CY, Chou MC, Lin MC, Shen CH, Chao CN, Jou YC, Chang D, Wang M. Peptide-guided JC polyomavirus-like particles specifically target bladder cancer cells for gene therapy. Sci Rep 2021;11:11889. [PMID: 34088940 DOI: 10.1038/s41598-021-91328-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol 2021;14:85. [PMID: 34059100 DOI: 10.1186/s13045-021-01096-0] [Cited by in Crossref: 88] [Cited by in F6Publishing: 103] [Article Influence: 88.0] [Reference Citation Analysis]
18 Zhang Y, Benassi E, Shi Y, Yue X, Cui L, Yang S, Liu Z, Guo X. Modified biomimetic core–shell nanostructures enable long circulation and targeted delivery for cancer therapy. New J Chem 2021;45:21359-68. [DOI: 10.1039/d1nj04407a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]